The headline figures describe two related but different measures. An estimated 7.4 million Americans age 65 and older have clinical Alzheimer’s dementia in 2026, while $409 billion is the projected cost of health care, long-term care, and hospice for people 65 and older with Alzheimer’s or other dementias. The spending estimate is expressed in 2026 dollars and does not include unpaid caregiving. For example, a daughter who reduces her work hours to supervise a parent contributes real economic value, but that lost time is outside the $409 billion total.
These figures come from the Alzheimer’s Association’s peer-reviewed report, [“2026 Alzheimer’s Disease Facts and Figures,”](https://doi.org/10.1002/alz.71345) first published April 21, 2026. The distinctions matter: 7.4 million is an estimate for older adults with clinical Alzheimer’s dementia, not a count of every American with dementia, and $409 billion covers multiple forms of dementia rather than Alzheimer’s alone. About 74% of the estimated 7.4 million people are age 75 or older. That concentration in later life helps explain why dementia increasingly intersects with chronic illness, mobility limitations, caregiver availability, housing decisions, and the need for long-term support.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Do the 2026 Alzheimer’s Facts of 7.4 Million Americans and $409 Billion Really Mean?
- What the $409 Billion Dementia Care-Cost Projection Includes
- Unpaid Dementia Care Is a Separate $446.3 Billion Burden
- How Families Can Use the 2026 Cost Figures for Care Planning
- Broader Cost Estimates, Mortality Data, and Their Limitations
- Alzheimer’s Prevalence and Care Costs Beyond 2026
- What Kisunla Changes—and What It Does Not
- Frequently Asked Questions
What Do the 2026 Alzheimer’s Facts of 7.4 Million Americans and $409 Billion Really Mean?
The 7.4 million figure refers specifically to Americans age 65 and older estimated to have clinical Alzheimer’s dementia in 2026. It does not include every younger person with Alzheimer’s, everyone with another type of dementia, or people with biological Alzheimer’s changes who have not developed clinical dementia. It is a population estimate rather than a registry-based count of individually confirmed cases. About 1 in 9 Americans age 65 and older, or 11%, has clinical Alzheimer’s dementia.
Prevalence rises sharply with age: it is estimated at 5.2% among people ages 65–74 and 35.8% among those 85 and older. In practical terms, Alzheimer’s dementia is present in roughly one of every three people in the oldest age group, compared with about one of every 19 people in the youngest group covered by these estimates. Age-related prevalence does not mean significant memory loss is a normal or inevitable part of aging. A 70-year-old who occasionally misplaces a name is not statistically or clinically equivalent to someone whose memory, judgment, or orientation is disrupting medication management, finances, driving, or daily routines. Percentages describe populations; diagnosis requires an individual medical assessment.
What the $409 Billion Dementia Care-Cost Projection Includes
The $409 billion estimate represents projected 2026 payments for health care, long-term care, and hospice for people age 65 and older with Alzheimer’s or other dementias. It includes costs such as hospital care, physician services, skilled nursing, residential long-term care, home health services, and end-of-life care. It should not be described as the cost of Alzheimer’s alone. Medicare and Medicaid are projected to pay $263 billion, or 64% of the total.
Out-of-pocket spending is projected at $103 billion, or 25%. That out-of-pocket category can translate into difficult household decisions: a spouse may need to pay for home-care shifts, transportation, medical equipment, or a residential-care copayment while also meeting ordinary housing and food expenses. The national projection is not a price list for an individual family. A person living safely at home with limited paid assistance may generate very different costs from someone with repeated hospitalizations and several years of nursing-home care. Insurance coverage, Medicaid eligibility, veterans’ benefits, geography, disease stage, and the availability of family help can all change who pays and how much.
Unpaid Dementia Care Is a Separate $446.3 Billion Burden
More than 12 million unpaid caregivers provided 19.6 billion hours of care in 2025, with an estimated value of $446.3 billion. These hours may involve preparing meals, managing medication, arranging appointments, handling finances, preventing wandering, helping with bathing, or remaining available overnight in case of confusion or a fall. The $446.3 billion valuation should not simply be added to the $409 billion spending projection and presented as one directly comparable bill. The former assigns economic value to unpaid time, while the latter measures projected payments for specified care services.
They reveal different dimensions of dementia’s impact and must be labeled separately. A concrete example shows why the distinction matters. If a son spends 20 hours each week helping his mother and receives no wages, Medicare records no payment for those hours. If a home-care agency supplies the same assistance for a fee, the transaction may appear in paid-care spending. The need can be similar even though the accounting is different.
How Families Can Use the 2026 Cost Figures for Care Planning
Families can begin by separating medical coverage from custodial care. Medicare may cover qualifying medical treatment, short-term skilled services, and hospice, but it generally does not function as unlimited coverage for years of help with supervision and routine daily activities. Medicaid can cover extensive long-term services for eligible people, although financial and functional requirements vary by state. A practical care inventory can identify both visible and hidden costs.
Families can record paid home-care hours, transportation, home modifications, medication, adult day services, legal work, residential-care charges, and unpaid caregiver time. Comparing the cost of several home-care shifts with assisted living is useful, but price should not be the only consideration: home care may preserve familiarity, while residential care may offer more consistent staffing and overnight supervision. Planning should occur before a crisis limits the person’s ability to participate. Useful steps can include reviewing powers of attorney, advance directives, insurance coverage, benefit eligibility, account access, driving plans, and preferences for future care. Families should be cautious about assuming that one relative can provide increasing supervision indefinitely without effects on employment, sleep, health, and household finances.
Broader Cost Estimates, Mortality Data, and Their Limitations
A separate peer-reviewed study, [“The Cost of Dementia in the United States in 2026,”](https://doi.org/10.1002/alz.71480) estimates the broader national burden at $818 billion. That calculation includes quality-of-life losses, unpaid care, and lost earnings in addition to conventional spending. It does not contradict the $409 billion projection; it answers a broader economic question using a different definition of cost. Official death certificates recorded 116,022 deaths from Alzheimer’s disease in 2024.
Alzheimer’s was the sixth-leading cause of death overall and the fifth-leading cause among Americans age 65 and older. Death-certificate statistics should not be treated as a count of everyone who died while living with dementia, because the figures depend on how the underlying cause of death was recorded. Cost and mortality rankings can also obscure daily variation. Two people with the same diagnosis may follow very different courses: one may remain at home with modest assistance, while another experiences falls, infections, delirium, behavioral symptoms, or repeated hospital care. National totals are valuable for policy and planning, but they cannot predict an individual’s care trajectory.
Alzheimer’s Prevalence and Care Costs Beyond 2026
Absent preventive or curative breakthroughs, the report projects that 13.8 million Americans age 65 and older could have clinical Alzheimer’s dementia by 2060. This is a projection based on assumptions about population aging and disease prevalence, not a forecasted certainty.
Payments for health care, long-term care, and hospice are projected to approach $1 trillion by 2050. The report warns that this estimate does not account for recently approved disease-slowing drugs or future breakthroughs. For example, a therapy could add medication, imaging, infusion, and monitoring expenses while potentially changing later patterns of disability and care use.
What Kisunla Changes—and What It Does Not
Kisunla, the brand name for donanemab-azbt, is already FDA-approved; it is not awaiting approval. The FDA approved it on July 2, 2024, as an intravenous infusion administered every four weeks. Treatment should be initiated only in the population studied: people with amyloid-confirmed mild cognitive impairment or mild dementia due to Alzheimer’s disease.
It is not an established treatment for moderate or severe dementia, and confirming eligibility requires more than a complaint of memory loss. The pivotal randomized, placebo-controlled trial enrolled 1,736 participants. At week 76, donanemab produced a 2.92-point difference from placebo on the integrated Alzheimer’s Disease Rating Scale and a −0.70-point difference on the Clinical Dementia Rating–Sum of Boxes. These results indicate slower clinical decline, not reversal of impairment or a cure, and treatment decisions require individualized discussion of eligibility, monitoring, risks, and expected benefit.
Frequently Asked Questions
Do 7.4 million Americans of all ages have Alzheimer’s dementia?
No. The estimate applies to Americans age 65 and older with clinical Alzheimer’s dementia. It is not an all-ages count and does not include every form of dementia.
Is $409 billion the cost of Alzheimer’s disease alone?
No. It is projected 2026 spending on health care, long-term care, and hospice for people age 65 and older with Alzheimer’s or other dementias.
Does the $409 billion include unpaid family caregiving?
No. More than 12 million caregivers provided 19.6 billion unpaid hours in 2025, valued separately at $446.3 billion.
Who is expected to pay most of the $409 billion?
Medicare and Medicaid are projected to cover $263 billion, or 64%. Out-of-pocket spending is projected at $103 billion, or 25%.
Is Kisunla a cure for Alzheimer’s disease?
No. In its pivotal trial, Kisunla slowed clinical decline compared with placebo. It did not reverse Alzheimer’s or cure the disease.
